Novo Nordisk Teams With Aspect Biosystems On Diabetes Cell Therapy

 
• By Joseph Haas

Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.

3D printer
Novo Nordisk/Aspect alliance with apply 3D printing to cell therapy • Source: Shutterstock

More from Strategy

More from Business